[Comment] Combining immunotherapy with stereotactic body radiation therapy in localised non-small-cell lung cancer

A comment published alongside The Lancet discusses the phase 3 SWOG/NRG S1914 randomised trial led by Megan E Daly and colleagues in the USA. The trial tested whether perioperative atezolizumab, given neoadjuvantly, concurrently and as adjuvant, with stereotactic body radiation therapy improves outcomes in high-risk, medically inoperable early-stage non-small-cell lung cancer. Its primary endpoint compares overall survival in 210 patients given atezolizumab plus SBRT versus 207 given SBRT alone.